Dr. Primo Lara on the need for multidisciplinary care in kidney cancer

"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

Trajectory inference analysis pointed to SIX2+CITED1+ as the nephrogenic cancer stem cells at the origin of Wilms tumor.

Adding cabozantinib to nivolumab/ipilimumab improved PFS in frontline renal cell carcinoma; however, there was increased toxicity with the triplet, including more adverse event–related discontinuations.

The phase 3 RENOTORCH study is comparing the combination of the PD1-inhibitor toripalimab and axitinib with single-agent sunitinib in patients with renal cell carcinoma.

Results from the phase 1 TRAVERSE trial showed signals of anti-tumor activity with the CAR T-cell therapy ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.